A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 165 participants.

Also called NCT07023614

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 165 participants (planned count) (from the registry)
Sponsor
Imbria Pharmaceuticals, Inc. (from the registry)
Registry
  • NCT NCT07023614
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Austria, Belgium, France, Germany, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07023614. Randomized; triple masking; primary purpose treatment. Start 2025-10-06 (actual); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Acronym
FORTITUDE-HCM
Condition
Non-obstructive Hypertrophic Cardiomyopathy
Intervention (Drug)
Ninerafaxstat 200mg MR
Intervention (Drug)
Placebo
Lead sponsor
Imbria Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct07023614
Content hash
76d3aa8311515692b73c0e8a38f654437f4b645ee1a1559d16af9f00f7e4b72d